In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos

Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible.

Two research technician positions are immediately available in my lab @HopkinsMedicine @hopkinskimmel. You will be working on KRAS targeting in solid cancer. If interested, please apply here: https://t.co/DbToAS15cw https://t.co/3YKiHIWS7s

Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.

Out today in @CD_AACR our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper https://t.co/0OXSB72rXA and a thread👇:

Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to @NouraChoudhury @YoninaMG @NeilVasan and the many contributing authors!!

Aaaaand we're back!! 9 years really flew by since I was last here while working at #MSKCC; now as a #HOfellow @ClevelandClinic. Especially humbled to reconnect with a close friend and AMAZING mentor @alexdrilon at #ASCO22!!

Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation.

RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!

The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.

Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to @ASCO for the opportunity to present, @GarridoLagunaMD for an excellent discussion, collaborators, and patients. #ASCO2021

I’m honored to be among the #ConquerCancer Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research opportunities possible. Give to the @ASCO CONQUERS CANCER Fund to help fuel the next generation of researchers  https://t.co/zwZIF01Ujp #ASCO21

Congratulations to @NouraChoudhury on her @ConquerCancerFd @ASCO Young Investigator Award. I'm lucky to co-mentor her with @HelenaYu923 . She has an interesting trial combining amivantamab and lazertinib in patients with EGFR mutant NSCLC progressing in the CNS (almost open!).

RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through our partnership with @LUNGevity and a generous donation-matching program, we hope to fund lifesaving research. Join us at https://t.co/XkTH53t2ng #RETcancer

Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients.

MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by @alexdrilon & @RobinGuo5 which found MET expression to predict TKI response in MET Ex 14-altered NSCLC. Twists & turns of the ever-evolving NSCLC biomarker story!

A call for rational type II TKI development. Seen through the lens of next-gen TRK inhibitor resistance in TRK fusion+ cancers. 🤓Highlights the utility of TKI type switching as a strategy for on-target resistance in oncogene-driven tumors. @EmilianoCocco2 @ScaltritiLab

Wonderful team effort from many people around the world. I want to take a second to especially thank our patients and families without whom we could not have accomplished this. We are in your debt. Shout out to the RET Renegades!

Excited to chair a free online lung cancer @OncLive webinar with @benlevylungdoc covering the latest topics in management of #NSCLC Wednesday, October 14, 6:30pm EST featuring expert faculty: @alexdrilon @IbiayiMD @Joshua_Reuss @kamarrone #LCSM https://t.co/y5tdwYNiyM